[go: up one dir, main page]

WO2009022179A3 - Glucokinase activators in the treatment of osteoarthritis - Google Patents

Glucokinase activators in the treatment of osteoarthritis Download PDF

Info

Publication number
WO2009022179A3
WO2009022179A3 PCT/GB2008/050700 GB2008050700W WO2009022179A3 WO 2009022179 A3 WO2009022179 A3 WO 2009022179A3 GB 2008050700 W GB2008050700 W GB 2008050700W WO 2009022179 A3 WO2009022179 A3 WO 2009022179A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteoarthritis
treatment
glucokinase activators
prophylaxis
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/050700
Other languages
French (fr)
Other versions
WO2009022179A2 (en
Inventor
Sarah Maria Valentin Brockbank
Maurice Ronald Charles Needham
Kristen Mary Clements
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Publication of WO2009022179A2 publication Critical patent/WO2009022179A2/en
Publication of WO2009022179A3 publication Critical patent/WO2009022179A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for the prophylaxis and/or therapy of osteoarthritis (OA) which method comprises administering to a mammalian subject in need of such prophylaxis and/or therapy a pharmaceutically effective amount of a glucokinase (GLK) activator.
PCT/GB2008/050700 2007-08-14 2008-08-13 Glucokinase activators in the treatment of osteoarthritis Ceased WO2009022179A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96465107P 2007-08-14 2007-08-14
US60/964,651 2007-08-14

Publications (2)

Publication Number Publication Date
WO2009022179A2 WO2009022179A2 (en) 2009-02-19
WO2009022179A3 true WO2009022179A3 (en) 2009-06-04

Family

ID=39933330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050700 Ceased WO2009022179A2 (en) 2007-08-14 2008-08-13 Glucokinase activators in the treatment of osteoarthritis

Country Status (1)

Country Link
WO (1) WO2009022179A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152749A (en) 2008-05-16 2014-11-28 Takeda California Inc Pyrazole and fused pyrazole glucokinase activators
US20110218116A1 (en) * 2010-03-05 2011-09-08 The Curators Of The University Of Missouri Biomarkers of osteoarthritis
ES2624780T3 (en) 2010-03-31 2017-07-17 The Scripps Research Institute Cell reprogramming

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052869A1 (en) * 2002-12-12 2004-06-24 F. Hoffmann-La Roche Ag 5-substituted-pyrazine or pyridine glucokinase activators
WO2005121110A1 (en) * 2004-06-05 2005-12-22 Astrazeneca Ab Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2006112549A1 (en) * 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007028135A2 (en) * 2005-09-01 2007-03-08 Takeda Pharmaceutical Company Limited Imidazopyridine compounds
WO2007053345A1 (en) * 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
WO2007089512A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052869A1 (en) * 2002-12-12 2004-06-24 F. Hoffmann-La Roche Ag 5-substituted-pyrazine or pyridine glucokinase activators
WO2005121110A1 (en) * 2004-06-05 2005-12-22 Astrazeneca Ab Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2006112549A1 (en) * 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP1873144A1 (en) * 2005-04-20 2008-01-02 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007028135A2 (en) * 2005-09-01 2007-03-08 Takeda Pharmaceutical Company Limited Imidazopyridine compounds
WO2007053345A1 (en) * 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
WO2007089512A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COGHLAN MATTHEW ET AL: "Glucokinase activators in diabetes management.", EXPERT OPINION ON INVESTIGATIONAL DRUGS FEB 2008, vol. 17, no. 2, February 2008 (2008-02-01), pages 145 - 167, XP002521218, ISSN: 1744-7658 *
COMBETTES M ET AL: "Newly approved and promising antidiabetic agents", THERAPIE, DOIN, PARIS, FR, vol. 62, no. 4, 1 July 2007 (2007-07-01), pages 293 - 310, XP008104223, ISSN: 0040-5957 *
FYFE M C T ET AL: "Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions", DIABETOLOGIA 200706 DE, vol. 50, no. 6, June 2007 (2007-06-01), pages 1277 - 1287, XP002521216, ISSN: 0012-186X *
MILLIGAN P A ET AL: "The consequences of H2 receptor antagonist - piroxicam coadministration in patients with joint disorders", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 1993 DE, vol. 45, no. 6, 1993, pages 507 - 512, XP008104387, ISSN: 0031-6970 *
TETLOW LYNNE C ET AL: "Histamine, histamine receptors (H-1 and H-2), and histidine decarboxylase expression by chondrocytes of osteoarthritic cartilage: an immunohistochemical study", RHEUMATOLOGY INTERNATIONAL, vol. 26, no. 2, December 2005 (2005-12-01), pages 173 - 178, XP002521217, ISSN: 0172-8172 *

Also Published As

Publication number Publication date
WO2009022179A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2009120361A3 (en) Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
MY184914A (en) Methods of administering pirfenidone theraphy
AU2007221366A8 (en) Oxyntomodulin derivatives
PH12013501791B1 (en) Uses of dpp-iv inhibitors
MX2019005130A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin.
WO2008124384A3 (en) Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
WO2009086072A3 (en) Therapy of rituximab-refractory rheumatoid arthritis patients
AU2012354056A8 (en) Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
WO2009150547A3 (en) 2-pyridyl substituted imidazoles as alk4 and/or alk4 inhibitors
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
SG196863A1 (en) Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
TW200800954A (en) Novel crystal modifications
MY160406A (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
IN2014DN08385A (en)
MX2009010483A (en) 5-oxo-isoxazoles as inhibitors of lipases and phospholipases.
WO2009022179A3 (en) Glucokinase activators in the treatment of osteoarthritis
WO2010065069A3 (en) Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
WO2008089494A3 (en) Methods of use of epsilon inhibitor compounds for the attenuation of pain
UA35391U (en) Method for laser surgical resection of oligoastrocytoma of cerebral hemisphere with median extension
UA29775U (en) Kushnirchuk's technique for umbilicus formation
UA85959C2 (en) Method for treating denture-associated stomatitis in setting of metabolic syndrome
UA35036U (en) Method for treating steatosis of liver in adult patients
UA55888U (en) Method for treating degenerative-and-dystrophic vertebral diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788671

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08788671

Country of ref document: EP

Kind code of ref document: A2